Physician profile
Daniel K Gordon
NPI 1821020686
$610.20
in general payments reported to CMS, 2019-2025
11 companies · $49.10 in 2025
The $49.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2022: $118 · 2023: $317 · 2025: $49.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $294.59 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Amgen INC. | $75.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $47.84 | 2023 | Farxiga |
| Lilly USA, LLC | $30.83 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $30.13 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $29.17 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $23.71 | 2019 | |
| Pfizer INC. | $23.32 | 2022 | |
| Novo Nordisk INC | $14.65 | 2023 | Rybelsus, Ozempic |
| Allergan, INC. | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.